- Poster presentation
- Open Access
Diagnostic value and clinical significance of antibodies against a modified citrullinated vimentin (anti-MCV) in patients with early juvenile arthritis
Pediatric Rheumatology volume 6, Article number: P9 (2008)
To investigate the diagnostic value and clinical significance of anti-MCV in pts with early JA.
Patients and methods: 85 pts were included in the study (M/F = 36/49) in the age of 1,5–16 years (mean 8.7 ± 4.9 years). Systemic JA – 10 pts (11.8%), poly – 37 (43.5%), oligo-38 (44.7%). Duration of disease was < 6 months. We studied also 54 pts with early RA, 28 pts with undifferentiated arthritis (UA) and 14 healthy children. Anti-MCV was measured in serum by enzyme-linked immunosorbent assay (ELISA) using the cut off value of 25 U/ml. IgM RF and hsCRP-by laser-nephelometry assay on BN-100 analyser.
Anti-MCV levels were elevated in 23 (27.1%) pts with early JA, in systemic – 2 (20%), poly – 11(29.7%), oligo-10 (26.3%). In pts with RF positive JA – 5 (100%), in RF negative pts- 7(17.1%) (p < 0.001). In the control groups: 34/54 (62.9%) adults with early RA (p < 0,001), 14/28 (50%) with UA (p < 0.05), none of the healthy children showed anti-MCV positivity. The median anti-MCV level in JA was 16.8 U/ml (IR: 11.5–26.4), in RF+ pts (M-834.9; IR 539.3–1149.3 U/ml) was higher than in RF-pts (M-14.5; IR:5.7–22.0 U/ml) (p < 0.001). Anti-MCV correlated with parameters of disease activity (hs CRP, ESR), with RF and anti-CCP positivity. Anti-MCV were not associated with ANA.
Determination of anti-MCV levels especially together with RF and anti-CCP in pts with early JA can indicate evolution JRA similar RA in adults. Anti-MCV levels correlated with common parameters of inflammation and acute phase response and may be useful to monitor disease activity.
About this article
Cite this article
Salugina, S., Fedorov, E., Alexandrova, E. et al. Diagnostic value and clinical significance of antibodies against a modified citrullinated vimentin (anti-MCV) in patients with early juvenile arthritis. Pediatr Rheumatol 6, P9 (2008). https://doi.org/10.1186/1546-0096-6-S1-P9
- Public Health
- Clinical Significance
- Acute Phase
- Immunosorbent Assay